# Schedule 2: Information Requested – Response form

**[*Insert Date***]

Andrew Oliver (Senior Therapeutic Group Manager)

Craig Butler (Manager Procurement and Contracts)  
PHARMAC  
PO Box 10-254  
Wellington 6143  
New Zealand

Via email to [procurement@pharmac.govt.nz](mailto:procurement@pharmac.govt.nz)

Dear Sirs

**Information regarding research, manufacturing and supply of COVID-19 vaccines.**

In response to PHARMAC’s request for information (**RFI**) dated 13 July 2020, we put forward the following information in respect of **COVID-19 vaccines**:

**Our contact details:**

|  |  |
| --- | --- |
| Name of organisation |  |
| Contact person |  |
| Address |  |
| Phone |  |
| Facsimile |  |
| Email address |  |

1. **Are you willing to be contacted for any follow up questions relating to your responses to this RFI?**

Yes / No *(delete as appropriate)*

* 1. **If you responded ‘No’ to question 1 above, please tell us why**

|  |
| --- |
|  |

**Interest**

1. **Does your organisation have an interest in COVID-19 vaccine development, manufacture or supply? Please describe.**

|  |
| --- |
|  |

**Covid-19 vaccine candidates**

1. **Do you have, or are you planning to have a COVID-19 vaccine development programme?**

|  |
| --- |
|  |

1. **What technology platform is(are) your vaccine candidate(s) based on?**

|  |
| --- |
|  |

1. **Is your development in-house or in a partnership with other parties? Please describe.**

|  |
| --- |
|  |

1. **Have you previously commercialised a vaccine based on the same technology platform? Please describe.**

|  |
| --- |
|  |

**Intellectual Property**

1. **Please describe the ownership of intellectual property related to your vaccine candidates.**

|  |
| --- |
|  |

1. **Is your organisation considering opportunities to expand manufacturing capacity by allowing licenced manufacture in third party manufacturing facilities? Please provide details.**

|  |
| --- |
|  |

**Manufacturing capability/capacity**

1. **Please describe your anticipated COVID-19 vaccine manufacturing capacity, by year, for the next five years.**

|  |
| --- |
|  |

1. **What proportion of your existing or potential capacity for a COVID-19 vaccine, if any, has already been allocated to pre-commitments to purchasing arrangements?**

|  |
| --- |
|  |

1. **Is your organisation open to licencing manufacture in approved third party vaccine manufacturing facilities as part of your capacity planning?**

|  |
| --- |
|  |

**Global vaccine allocation plan**

1. **Does your organisation have, or is it intending to develop, a global COVID-19 vaccine allocation policy or plan?**

|  |
| --- |
|  |

1. **What are the guiding principles of any allocation plan? Please include any information relating to your plans to provide equitable supply to countries, including where you see New Zealand and Pacific countries sitting in this framework.**

|  |
| --- |
|  |

1. **What plans does your organisation have for allocating vaccine supply to New Zealand and Pacific countries? Please include information about possible timing and quantity of any allocations to New Zealand and Pacific countries.**

|  |
| --- |
|  |

1. **Has your organisation made, or is it intending to make any commitments to pooled global procurement initiatives such as the Gavi COVAX Facility or COVAX AMC?**

|  |
| --- |
|  |

1. **Has your organisation made, or is it intending to make any commitments to collaborative purchasing alliances such as the European Commission initiative, International Vaccine Alliance, International Buyers Club or other groupings of countries?**

|  |
| --- |
|  |

1. **What plans does your organisation have in relation to direct agreements with individual countries, including Advanced Purchase Agreements?**

|  |
| --- |
|  |

**Regulatory plans**

1. **Please describe your approach to securing regulatory approval around the world. Please describe the type of approach you would use for New Zealand and the sequencing of this relative to other countries.**

|  |
| --- |
|  |

1. **Would you consider New Zealand regulatory approval in parallel with other countries?**

|  |
| --- |
|  |

**Commercial interests**

1. **Please describe your organisation’s approach to the commercialisation of COVID-19 vaccines. To what extent do you consider the supply of COVID-19 vaccines to be a public good priority vs a commercial opportunity?**

|  |
| --- |
|  |

**Other relevant information**

1. **Please provide any other relevant information about your COVID-19 vaccine plans or capability that has not already been provided above.**

|  |
| --- |
|  |